Crohn's disease and ulcerative colitis: from epidemiology and immunobiology to a rational diagnostic and therapeutic approach

INDICE: The genetics of inflammatory bowel disease. Environmental factors in the epidemiology of inflammatory bowel disease.-The intestinal immune systemin health. Understanding the epithelial barrier in inflammatory bowel disease.- Intestinal microbiology and ecology in inflammatory bowel disease.- Microbial recognition and pathogen-associated molecular pattern (PAMP) receptors ininflammatory bowel disease. Inflammasomes in inflammatory bowel disease.-Antimicrobial peptides in inflammatory bowel disease. Vascular responses to intestinal inflammation in inflammatory bowel disease. Immunobiology of dendriticcells in inflammatory bowel disease.-Immunobiology of T-Cells in inflammatorybowel disease. Immunobiology of B-Cells in inflammatory bowel disease.-Immunobiology of monocytes and macrophages in inflammatory bowel disease. Immunobiology of epithelial cells in inflammatory bowel disease. The Th1, Th2 and Th17 paradigm in inflammatory bowel disease. Preclinical studies using mouse models of inflammatory bowel disease.- Enhanced endoscopy in inflammatory bowel disease. MRI in Inflammatory Bowel Disease. CT in inflammatory bowel disease.-Ultrasound in inflammatory bowel disease.-Laboratory evaluation including novel diagnostic markers of inflammatory bowel disease. Histology and pathology of inflammatory bowel disease. Activity indices based assessment of disease activityin inflammatory bowel disease.- Endoscopic assessment of disease activity andmucosal healing in inflammatory bowel disease.-Evaluation of quality of life in inflammatory bowel disease. The natural history of inflammatory bowel disease. Conventional medical management of Crohn’s disease: sulfasalazine. Conventional medical management of Crohn’s disease: corticosteroids.-Conventional medical management of Crohn’s disease: azathioprine and 6-mercaptopurine.- Conventional medical management of Crohn’s Disease: Methotrexate.-Biologic Treatmentof Crohn’s Disease: Adalimumab. Biologic Treatment of Crohn’s Disease: Certolizumab. Biologic Therapy of Crohn's disease: Infliximab.- Biologic Treatment of Crohn’s Disease: briakinumab and ustekinumab.-Biologic Treatment of Crohn’s Disease: natalizumab, vedolizumab and edrolizumab (rHUMab beta 7).-Conventional medical management of ulcerative colitis: sulfasalazine and 5-aminosalicylates.-Conventional medical management of ulcerative colitis: corticosteroids. Conventional medical management of ulcerative colitis: azathioprinetherapy: Azathioprine.- Conventional medical management of ulcerative colitis: cyclosporine. Conventional medical management of ulcerative colitis: tacrolimus.- Biologic therapy of ulcerative colitis: infliximab and adalimumab. Biologic therapy of ulcerative colitis: natalizumab, vedolizumab, edrolizumab (rHUMab beta 7). Probiotics, prebiotics, and antibiotics in medical management inflammatory bowel disease. Step-Up vs. Top-Down Approach in medical management of inflammatorybowel disease. Surgic

• ISBN: 978-1-4614-0997-7
• Editorial: Springer New York
• Encuadernacion: Cartoné
• Páginas: 798
• Fecha Publicación: 28/12/2011
• Nº Volúmenes: 1
• Idioma: Inglés